Arvinas’ Potential In Treating ER+, HER2- Breast Cancer (NASDAQ:ARVN)

Breast ultrasound exam



Arvinas (NASDAQ:ARVN) is a clinical-stage biotech firm pioneering therapies to treat severe diseases by degrading disease-causing proteins. Using their unique PROTAC Discovery Engine, they design PROTAC targeted protein degraders to utilize the body’s natural disposal system, aiming for advantages

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *